<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">FENOFIBRATE <img border="0" src="../images/pr.gif"/></span><br/>(fen-o-fi'brate)<br/><span class="topboxtradename">Tricor, </span><span class="topboxtradename">Luxacor, </span><span class="topboxtradename">Lofibra, Antara<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">antilipemic</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>48 mg, 50 mg, 154 mg, 160 mg tablets; 43 mg, 67 mg, 87 mg, 134 mg, 200 mg capsules or 50 mg, 100 mg, 150 mg, 160 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Fibric acid derivative with lipid-regulating properties. Lowers plasma triglycerides apparently by inhibiting triglyceride
         synthesis and, as a result, lowers VLDL production as well as stimulates the catabolism of triglyceride-rich lipoprotein (e.g.,
         VLDL). Produces a moderate increase in HDL cholesterol levels in most patients.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Indicated by reduction in the level of serum triglycerides; interferes with synthesis of serum triglycerides.</p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunctive therapy to diet for patients with high triglycerides.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to fenofibrate or other fibric acid derivatives (e.g., clofibrate, benzofibrate); liver or severe kidney
         dysfunction; unexplained liver function abnormality; primary biliary cirrhosis; preexisting gallbladder disease; pregnancy
         (category C); lactation; thrombocytopenia. Safety and efficacy in children are not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Concomitant therapy with HMG-CoA reductase inhibitors (e.g., lovastatin, pravastatin, simvastatin), oral anticoagulant medications;
         renal impairment, older adults; history of bleeding disorders; myelosuppression.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertriglyceridemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 54 mg q.d. (max: 160 mg/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Limit dose to 54 mg/d in older adults or those with impaired kidney function.</li>
<li>Give at least 1 h before or 46 h after cholestyramine.</li>
<li>Store at 15°30° C (59°86° F) in a tightly closed container and protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Asthenia, fatigue, infections, flu-like syndrome, localized pain, arthralgia. <span class="typehead">CNS:</span> Headache, paresthesia, dizziness, insomnia. <span class="typehead">CV:</span> Arrhythmia. <span class="typehead">GI:</span> Dyspepsia, eructation, flatulence, nausea, vomiting, abdominal pain, constipation, diarrhea, increased appetite. <span class="typehead">Respiratory:</span> Cough, rhinitis, sinusitis. <span class="typehead">Skin:</span> Pruritus, rash. <span class="typehead">Special Senses:</span> Earache, eye floaters, blurred vision, conjunctivitis, eye irritation, <span class="typehead">Urogenital:</span> Decreased libido, polyuria, vaginitis. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May potentiate anticoagulant effects of <b>warfarin;</b> combination with an <span class="classification">hmg-coa reductase inhibitor (statin)</span> may result in rhabdomyolysis or acute renal failure; <b>cholestyramine,</b> <b>colestipol</b> may decrease absorption (give fenofibrate 1 h before or 46 h after <span class="classification">bile acid sequestrants</span>); may increase risk of nephrotoxicity of <b>cyclosporine.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Well absorbed from the GI tract; absorption increased with food. <span class="typehead">Peak:</span> 68 h. <span class="typehead">Distribution:</span> 99% protein bound; excreted in breast milk. <span class="typehead">Metabolism:</span> Rapidly hydrolyzed by esterases to active metabolite, fenofibric acid. <span class="typehead">Elimination:</span> 60% excreted in urine, 25% in feces. <span class="typehead">Half-Life:</span> 20 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Periodically monitor lipid levels, liver functions, and CBC with differential.</li>
<li>Discontinue therapy after 2 mo if adequate lipid reduction is not achieved with the maximum dose of 201 mg/d.</li>
<li>Assess for muscle pain, tenderness, or weakness and, if present, monitor CPK level. Withdraw drug with marked elevations of
            CPK or if myopathy is suspected.
         </li>
<li>Monitor patients on coumarin-type drugs closely for prolongation of PT/INR.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Contact physician immediately if any of the following develops: Unexplained muscle pain, tenderness, or weakness, especially
            with fever or malaise; yellowing of skin or eyes; nausea or loss of appetite; skin rash or hives.
         </li>
<li>Inform physician regarding concurrent use of cholestyramine, oral anticoagulants, or cyclosporine.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>